# Roivant Sciences Ltd. (ROIV) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $34.93, market value $25.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Roivant Sciences Ltd. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3349.8×**. Each dollar of revenue is priced at 3349.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 6.0×**. The shares trade at 6.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.3%** (5-yr avg -12.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -6.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -13.3%**. Return on all capital, debt included, is -13.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -4.7%**. Each dollar of assets produces -4.7% of profit.

## Growth
- **Revenue growth (1 yr): -71.6%** (3-yr -36.0%/yr, 5-yr -19.1%/yr). Revenue fell 71.6% over the last year, against -19.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -125.0%**. Earnings per share fell 125.0%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.10**. Debt is 0.10 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.7×**. It would take 1.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 18.37** (quick 18.37). Current assets cover the next year's liabilities 18.37 times.
- **Altman Z-score: 38.21**. A Z-score of 38.21 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Roivant Sciences Ltd. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 177.9%** (YTD 61.0%, 3-mo 22.2%). The shares are up 177.9% over twelve months including dividends.
- **From 52-week high: -8.0%** (170.8% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 1.10** (volatility 43%). Beta of 1.10 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ROIV · Page: https://foliofundamentals.com/stocks/roiv

Not investment advice.